Company intelligence / Profile preview

Oscotec Inc.

Seongnam-si, Gyeonggi-do, South Koreaoscotec.com ↗

Overview

Oscotec has multiple drug candidates in clinical development:

SKI-O-703 (SYK inhibitor) completed Phase 2 for ITP and rheumatoid arthritis.
SKI-G-801 (FLT3/AXL inhibitor) in Phase 1 for AML and solid tumors.
Lazertinib (EGFR inhibitor) in Phase 3 for NSCLC; FDA approval with amivantamab for NSCLC as of August 2024.
Anti-Tau antibody in early-phase trials for Alzheimer’s disease[1][2].

Therapeutic areas: HematologyImmunologyOncologyNeurology
Modalities: Small moleculesmonoclonal antibodies (mAbs)functional biomaterials
Industry: Biotech

5 assets

4 more assets in the full pipeline.

Yuhan PharmaceuticalAmivantamab partnership on lazertinibBiorevert Inc. co-development agreementKanaph Therapeutics co-development agreement[2]

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Oscotec Inc..